The BioNTech SE ADR BNTX slipped 7.29% to $115.62 Wednesday, on what proved to be an all-around rough trading session for the ...

UBS analyst Eliana Merle maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $131.00. The ...

Targeting the KP.2 strain is expected to provide better protection against COVID-19 based on current data. The 2024-2025 mRNA COVID-19 vaccines will include a monovalent component that corresponds to ...

The summer surge of COVID-19 has been decreasing in Sonoma County in early September, but the county’s health officer warns ...

The BioNTech SE ADR BNTX rallied 1.00% to $124.71 Tuesday, on what proved to be an all-around mixed trading session for the ...

The company reported Health Canada authorized the use of its Spikevax KP.2 shot for those aged six months and older. Last ...

Fintel reports that on September 17, 2024, Jefferies upgraded their outlook for BioNTech SE - Depositary Receipt () (NasdaqGS ...

Today, Benzinga 's options scanner spotted 26 uncommon options trades for BioNTech. This isn't normal. The overall sentiment ...

BioNTech (BNTX) stock traded higher on Tuesday after Jefferies upgraded the COVID-19 vaccine maker to Buy, citing the ...

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...

The latest flu vaccines are now available, and just like the COVID-19 shots, it's recommended to get the flu shot in ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...